CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 996 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02596958
NCT02596958N/ACompleted
CompareCT.gov

Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology

Hoffmann-La Roche·observational·Posted Nov 4, 2015·Updated Apr 4, 2016

In Brief

An observational study evaluating Bevacizumab for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 996 participants across 1 site.

Detailed Summary

The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in participants with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology with focus on adenocarcinoma and elderly patients in daily routine.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 2015
Enrollment StartSep 1, 2007
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 10.7 years ago

Interventions

Bevacizumabdrug

Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.